This is a listing of Requests for Applications (RFA), Program Announcements (PA), and Notices specific to the group's key programs.
Standard submission dates apply for all listings, unless otherwise noted.
Notice: Internet links not permitted in NIH Grant Applications
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
Title |
Announcement # | Expiration Date | Research Focus |
|---|---|---|---|
| Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) | PA-20-227 | 04/16/2023 |
|
| Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research | PA-18-876 (R01 Clinical Trial Not Allowed) | 09/08/2021 |
|
| Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research | PA-18-902 (R01 Clinical Trial Optional) | 09/08/2021 |
|
| Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression | PA-18-739 (R21 Clinical Trial Optional) | 05/08/2021 |
|
| Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression | PA-18-738 (R01 Clinical Trial Optional) | 05/08/2021 |
|
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 - Clinical Trials Not Allowed) | PAR-18-317 | 10/09/2020 |
|
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed) | PAR-18-310 | 10/09/2020 |
|
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-252 (R21 Clinical Trial Optional) | 11/09/2021 |
|
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-251 (R01 Clinical Trial Optional) | 11/09/2021 |
|
| Basic Research in Cancer Health Disparities | PAR-18-655 (R21 Clinical Trial Not Allowed) | 11/20/2020 |
|
| Basic Research in Cancer Health Disparities | PAR-18-654 (R01 Clinical Trials Not Allowed) | 11/20/2020 |
|
| Biology of Bladder Cancer | PAR-19-183 (R01 Clinical Trial Optional) | 05/08/2022 |
|
| Biology of Bladder Cancer | PAR-19-184 (R21 Clinical Trial Optional) | 05/08/2022 |
|
| Biology of Lung, and Head and Neck Preneoplasias | PA-17-459 (R01) | 01/08/2021 |
|
| Biology of Lung, and Head and Neck Preneoplasias | PA-17-460 (R21 - Clinical Trial Not Allowed) | 01/08/2021 |
|
| Cancer Prevention and Control Clinical Trials Grant Program | PAR-18-559 (R01 Clinical Trial Required) | 01/08/2021 |
|
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-19-113 (R01 Clinical Trial Optional) | 01/08/2022 |
|
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies | PAR-19-325 (R01 Clinical Trial Optional) | 02/12/2022 |
|
| Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment | PA-18-917 (R01 - Clinical Trial Optional) | 09/08/2021 |
|
| Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required) | PAR-20-134 | 06/09/2021 |
|
| Diet and Physical Activity Assessment Methodology | PA-18-856 (R01 Clinical Trial Not Allowed) | 09/08/2021 |
|
| Diet and Physical Activity Assessment Methodology | PAR-18-857 (R21 Clinical Trial Not Allowed) | 09/08/2021 |
|
| Exploratory/Developmental Clinical Research Grants in Obesity | PA-18-720 (R21 Clinical Trial Optional) | 05/08/2021 |
|
| Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required) | PAR-20-133 | 06/09/2021 |
|
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer | PAR-19-264 (R01 Clinical Trial Optional) | 12/11/2021 |
|
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | PA-19-111 (R21 Clinical Trial Optional) | 01/08/2022 |
|
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | PA-19-112 (R01 Clinical Trial Optional) | 01/08/2022 |
|
| Mechanisms, Models, Measurement, and Management in Pain Research | PA-18-141 (R01 Clinical Trial Optional) | 05/08/2021 |
|
| Mechanisms, Models, Measurement, and Management in Pain Research | PA-18-159 (R21 Clinical Trial Optional) | 05/08/2021 |
|
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain | PA-19-200 (R01 Clinical Trial Optional) | 05/08/2022 |
|
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain | PA-19-201 (R21 Clinical Trial Optional) | 05/08/2022 |
|
| Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer | PAR-19-199 (R21 Clinical Trial Not Allowed) | 11/09/2021 |
|
| Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer | PAR-19-198 (R01 Clinical Trial Not Allowed) | 11/09/2021 |
|
| NCI Clinical and Translational Exploratory/Developmental Studies | PAR-19-356 (R21 Clinical Trial Optional) | 07/21/2022 |
|
| Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine | PAR-18-841 (U24 - Clinical Trial Optional) | 06/15/2021 |
|
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival | PAR-18-893 (R01 Clinical Trial Optional) | 09/08/2021 |
|
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival | PAR-18-892 (R21 Clinical Trial Optional) | 09/08/2021 |
|
| Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | PAR-20-053 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
|
| Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) | PAR-20-266 | 06/20/2023 |
|
| Research Answers to National Cancer Institute's (NCI) Provocative Questions | RFA-CA-20-004 (R01 Clinical Trial Optional) | 11/18/2020 |
|
| Research Answers to National Cancer Institute's (NCI) Provocative Questions | RFA-CA-20-005 (R21 Clinical Trial Optional) | 11/18/2020 |
|
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-277 (R21 Clinical Trials Not Allowed) | 09/08/2022 |
|
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-276 (R01 Clinical Trial Not Allowed) | 09/08/2022 |
|
| Symptom Cluster Characterization in Chronic Conditions | PA-17-462 (R01) | 01/08/2021 |
|
| Symptom Cluster Characterization in Chronic Conditions | PA-17-461 (R21) | 01/08/2021 |
|
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research | PAR-18-913 (U01 Clinical Trial Not Allowed) | 08/12/2021 |
|
| Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) | PA-20-252 | 04/16/2022 |
|
